MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Authors: Brigitte Dréno, John F Thompson, B. Mark Smithers, Mario Santinami, Thomas Jouary, Ralf Gutzmer, E. Levchenko, Piotr Rutkowski, Jean-Jacques Grob, S.I. Korovin, Kamil Drucis, Florent Grange, L. Machet, Peter Hersey, Ivana Krajsová, Alessandro Testori, Robert M. Conry, B. Guillot, Wim H.J. Kruit, Lev Demidov, John A. Thompson, Igor Bondarenko, Jarosław Jaroszek, Susana Puig, Gabriela Cinat, Axel Hauschild, Jelle J. Goeman, Hans C. van Houwelingen, Fernando Ulloa-Montoya, Andrea Callegaro, Benjamin Dizier, Bart Spiessens, Muriel Debois, Vincent Brichard, Jamila Louahed, Patrick Therasse, C. Debruyne, John M. Kirkwood - The Lancet 2018 cited by 198